253 related articles for article (PubMed ID: 9774374)
1. Effects of eprosartan on renal function and cardiac hypertrophy in rats with experimental heart failure.
Brodsky S; Gurbanov K; Abassi Z; Hoffman A; Ruffolo RR; Feuerstein GZ; Winaver J
Hypertension; 1998 Oct; 32(4):746-52. PubMed ID: 9774374
[TBL] [Abstract][Full Text] [Related]
2. Effects of enalapril and eprosartan on the renal vascular nitric oxide system in human essential hypertension.
Delles C; Jacobi J; John S; Fleischmann I; Schmieder RE
Kidney Int; 2002 Apr; 61(4):1462-8. PubMed ID: 11918753
[TBL] [Abstract][Full Text] [Related]
3. ADEPT: Addition of the AT1 receptor antagonist eprosartan to ACE inhibitor therapy in chronic heart failure trial: hemodynamic and neurohormonal effects.
Murdoch DR; McDonagh TA; Farmer R; Morton JJ; McMurray JJ; Dargie HJ
Am Heart J; 2001 May; 141(5):800-7. PubMed ID: 11320369
[TBL] [Abstract][Full Text] [Related]
4. Eprosartan reduces cardiac hypertrophy, protects heart and kidney, and prevents early mortality in severely hypertensive stroke-prone rats.
Barone FC; Coatney RW; Chandra S; Sarkar SK; Nelson AH; Contino LC; Brooks DP; Campbell WG; Ohlstein EH; Willette RN
Cardiovasc Res; 2001 Jun; 50(3):525-37. PubMed ID: 11376628
[TBL] [Abstract][Full Text] [Related]
5. Renal hemodynamic response to an angiotensin II antagonist, eprosartan, in healthy men.
Price DA; De'Oliveira JM; Fisher ND; Hollenberg NK
Hypertension; 1997 Aug; 30(2 Pt 1):240-6. PubMed ID: 9260987
[TBL] [Abstract][Full Text] [Related]
6. A double blind randomized trial to compare the effects of eprosartan and enalapril on blood pressure, platelets, and endothelium function in patients with essential hypertension.
Leu HB; Charng MJ; Ding PY
Jpn Heart J; 2004 Jul; 45(4):623-35. PubMed ID: 15353873
[TBL] [Abstract][Full Text] [Related]
7. Effects of spironolactone and eprosartan on cardiac remodeling and angiotensin-converting enzyme isoforms in rats with experimental heart failure.
Karram T; Abbasi A; Keidar S; Golomb E; Hochberg I; Winaver J; Hoffman A; Abassi Z
Am J Physiol Heart Circ Physiol; 2005 Oct; 289(4):H1351-8. PubMed ID: 15894569
[TBL] [Abstract][Full Text] [Related]
8. Renal and systemic effects of chronic blockade of ET(A) or ET(B) receptors in normal rats and animals with experimental heart failure.
Francis B; Winaver J; Karram T; Hoffman A; Abassi Z
J Cardiovasc Pharmacol; 2004 Nov; 44 Suppl 1():S54-8. PubMed ID: 15838359
[TBL] [Abstract][Full Text] [Related]
9. Potential of the angiotensin II receptor 1 blocker eprosartan in the management of patients with hypertension or heart failure.
Hollenberg NK
Curr Hypertens Rep; 2001 Sep; 3 Suppl 1():S25-8. PubMed ID: 11580885
[TBL] [Abstract][Full Text] [Related]
10. A dose-response study to assess the renal hemodynamic, vascular, and hormonal effects of eprosartan, an angiotensin II AT1-receptor antagonist, in sodium-replete healthy men.
Ilson BE; Boike SC; Martin DE; Freed MI; Zariffa N; Jorkasky DK
Clin Pharmacol Ther; 1998 Apr; 63(4):471-81. PubMed ID: 9585802
[TBL] [Abstract][Full Text] [Related]
11. Improvement of cardiac output in patients with severe heart failure by use of ACE-inhibitors combined with the AT1-antagonist eprosartan.
Gremmler B; Kunert M; Schleiting H; Ulbricht LJ
Eur J Heart Fail; 2000 Jun; 2(2):183-7. PubMed ID: 10856732
[TBL] [Abstract][Full Text] [Related]
12. Effect of angiotensin II antagonist eprosartan on hyperglycemia-induced activation of intrarenal renin-angiotensin system in healthy humans.
Osei SY; Price DA; Laffel LM; Lansang MC; Hollenberg NK
Hypertension; 2000 Jul; 36(1):122-6. PubMed ID: 10904023
[TBL] [Abstract][Full Text] [Related]
13. Effect of long-term eprosartan versus enalapril antihypertensive therapy on left ventricular mass and coronary flow reserve in stage I-II hypertension. Eprosartan Study Group.
Diamond JA; Gharavi A; Roychoudhury D; Machac J; Henzlova MJ; Travis A; Phillips RA
Curr Med Res Opin; 1999; 15(1):1-8. PubMed ID: 10216805
[TBL] [Abstract][Full Text] [Related]
14. Clinical profile of eprosartan.
Puig JG; López MA; Bueso TS; Bernardino JI; Jiménez RT;
Cardiovasc Drugs Ther; 2002 Dec; 16(6):543-9. PubMed ID: 12766389
[TBL] [Abstract][Full Text] [Related]
15. Effects of eprosartan versus enalapril in hypertensive patients on the renin-angiotensin-aldosterone system and safety parameters: results from a 26-week, double-blind, multicentre study. Eprosartan Multinational Study Group.
Gavras I; Gavras H
Curr Med Res Opin; 1999; 15(1):15-24. PubMed ID: 10216807
[TBL] [Abstract][Full Text] [Related]
16. Central inhibition of AT1receptors by eprosartan--in vitro autoradiography in the brain.
Muders F; Palkovits M; Bahner U; Kirst I; Elsner D; Jandeleit-Dahm K
Pharmacol Res; 2001 Mar; 43(3):251-5. PubMed ID: 11401417
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the angiotensin II type 1-receptor antagonist YM358 and the angiotensin-converting enzyme inhibitor enalapril in rats with cardiac volume overload.
Tokioka-Akagi T; Fujimori A; Shibasaki M; Inagaki O; Yanagisawa I
Jpn J Pharmacol; 2001 May; 86(1):79-85. PubMed ID: 11430476
[TBL] [Abstract][Full Text] [Related]
18. Potential renoprotective effects of the angiotensin receptor blocker eprosartan: a review of preliminary renal studies.
Rayner B; Jaeger B; Verboom CN; Pascoe M
Cardiovasc J S Afr; 2004; 15(1):32-7. PubMed ID: 14997235
[TBL] [Abstract][Full Text] [Related]
19. The angiotensin type 1 receptor antagonist, eprosartan, attenuates the progression of renal disease in spontaneously hypertensive stroke-prone rats with accelerated hypertension.
Abrahamsen CT; Barone FC; Campbell WG; Nelson AH; Contino LC; Pullen MA; Grygielko ET; Edwards RM; Laping NJ; Brooks DP
J Pharmacol Exp Ther; 2002 Apr; 301(1):21-8. PubMed ID: 11907153
[TBL] [Abstract][Full Text] [Related]
20. Impaired nitric oxide-mediated renal vasodilation in rats with experimental heart failure: role of angiotensin II.
Abassi ZA; Gurbanov K; Mulroney SE; Potlog C; Opgenorth TJ; Hoffman A; Haramati A; Winaver J
Circulation; 1997 Nov; 96(10):3655-64. PubMed ID: 9396468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
